Hope for transplant patients: new pill tested for Life-Threatening complication
NCT ID NCT07197112
Summary
This study is testing the safety and effectiveness of an experimental oral medication called gimacabtinib for patients with severe acute graft-versus-host disease (GVHD). It is for adults who have had a stem cell transplant and whose GVHD did not improve or got worse after trying a standard second-line treatment containing the drug ruxolitinib. The main goal is to see how many patients show a positive response to the new drug after 28 days of treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE GRAFT VERSUS HOST DISEASE GRADE II-IV are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.